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Wayne Luther Glore. Targeting Galectin-1 as a Potential Therapeutic 
for Glioblastoma (Under guidance from Arabinda Das & Michael 
Ostrowski) 
     Glioblastoma (GB) is classified by the World Health Organization 
(WHO) as a Grade IV astrocytoma characterized by a poor prognosis 
with a median survival time ranging from 15-16 months. The 
standard of care for GB is surgery followed by radiation and 
chemotherapy treatment with Temozolomide, but even with the 
aggressive treatment, GB recurrence occurs in approximately 90 % 
of the patient population. New treatment options have been FDA 
approved which include Novocure’s Optune Device and Genentech’s 
Avastin, but neither of these options drastically change survival time 
or quality of life. Galectin-1 (Gal-1), a protein with a high affinity to 
bind β-galactosides, has been implicated in other cancers such as 
renal cancer, liver cancer, and urothelial cancer and plays a role 
ranging from angiogenesis to altering the tumor microenvironment 
for immune suppression. Little research has been conducted 
investigating Gal-1’s role in GB so the aim of our in vitro and in vivo 
studies was to gain a better understanding of Gal-1’s potential 
mechanisms in GB and see the feasibility of Gal-1 inhibition as a 
potential treatment option. The data collected illustrated roles of Gal-
1 in angiogenesis, in apoptosis, and in facilitation of a hypoxic 
environment. Inhibition of Gal-1 shows signs of being a plausible 
treatment option especially if given coadjuvant to an Anti-VEGF 
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     Glioblastoma (GB) is categorized by the World Health 
Organization (WHO) as a grade IV astrocytic tumor and stems 
from astrocytes, a star shape glia cell that protects the brain 
from infections and diseases. The exact cause for the onset of 
the brain tumor is unknown but begins when astrocytes start to 
rapidly proliferate to form tumors due to variations in genetic 
expression that promote cell growth. GB can cause a multitude 
of symptoms that include invasion and decay of healthy brain 
tissue surrounding the tumor, pressure from fluids building up, 
and a disruption of cerebrospinal fluid circulation through the 
brain. The tumor is typically found in the cerebral hemispheres 
of the brain, but it has the capacity to occur at any location in 
the brain. It is a cancer that is plagued with low survival rates 
with the median survival rate at 12-18 months.  The disease’s 5- 
year survival rate is approximately 10%. There are many 
barriers that prevent development of effective treatment for GB. 
Barriers to Treatment 
     Multiple barriers thwart effective treatment of GB. First, GB 
has high heterogeneity regarding the genetic composition of the 
tumor. GB cells capitulate multiple neurodevelopmental and 
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lineage differentiation processes to become their specified 
neuronal cells in the brain.1 This differentiation of cells leads to 
the genetic diversity that encompasses GB. Second, genetic 
expression profile differs between patients with GB. No one or 
two genes are the primary genetic drivers for tumor growth and 
eventual GB. A list of several indicated genes for GB 
progression and sustained growth include TP 53, PTEN, EGFR, 
IDH 1, IDH 2, MAP 3K1, NF 1, TET 1, and FGFR4. Due to the 
multitude of different genes expressed and their mutations in 
GB, it is difficult to target a single gene that will have beneficial 
treatment for a vast subset of patients. Even if one specific gene 
became readily targetable  the treatment would still face 
difficulty in delivery to the tumor because of the blood brain 
barrier (BBB). 
     Advances in GB treatment prove futile due to the BBB, a 
defense system that limits the entry of molecules and blocks the 
entrance of toxins or infectious molecules into the brain. The 
BBB is the barrier between the cerebral capillary blood and the 
interstitial fluid of the brain consisting of capillary endothelial 
cells, basement membrane, neuroglial membrane, and glial 
podocytes, i.e., projections of astrocytes.2 Tight junctions are 
formed between the endothelial cells preventing entry from 
blood borne pathogens and other potential deleterious products. 
3 
 
Only certain products can bypass the blood brain barrier these 
include lipid soluble molecules, and receptor-mediated transport 
of glucose and ions to pass through. Drugs given by intravenous 
(IV) injection and subcutaneous injection have low probability of 
crossing the BBB and being delivered to the target site of the 
tumor. The inability to easily cross the BBB with innovative 
treatment ideas is a powerful barrier to new treatment methods 
being developed and eventually FDA approved. 
Recurrent Glioblastoma Progression 
     Recurrent GB occurs in majority of patients with initial GB. 
The difficulty resides in removing the whole tumor and infiltrating 
tissue around the tumor and complete resection is uncommon. 
No established standard of care has been established for 
recurrent GB and treatment generally consist of another round 
of tumor re-section followed by radiation and treatment with 
Temozolomide. Survival time is relatively low and still rest at a 
little over a year. Recurrent GB is less responsive to treatment 
and has a high rate of drug and radiation resistance. 
Current Standard of Care 
     The standard of care for initial GB is maximal surgical 
resection followed by radiotherapy then Temozolomide (TMZ). A 
new treatment Bevacizumab (Avastin) was investigated 
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specifically for recurrent GB, but overall survival (OS) was not 
increased only quality of life (QOL). The benefits of TMZ + 
Bevacizumab help with increased time of progression free 
survival. The current standard of care was established in 2005 
with maximal safe resection and then concomitant daily 
temozolomide and radiotherapy followed by adjuvant 
temozolomide showed improvement in median OS and 2-year 
survival.3 TMZ is a chemotherapy treatment that is an alkylating 
agent that binds to DNA in cancer cells preventing their division 
and growth. Clinicians and advancing research identified the 
importance of DNA repair protein O6-methylguanine-DNA 
methyltransferase (MGMT) in understanding the likeliness of 
tumor response to TMZ treatment. MGMT would repair the 
damaged DNA caused by TMZ but in cases where the MGMT is 
methylated it loses function and eventually degrades. Lack of 
methylation of the MGMT gene is associated with a stronger 
likeliness of TMZ resistance by the tumor in patients who have 
GB. 4-7 
Avastin: Potential Implications GB and Recurrent GB 
Treatment                  
   Bevacizumab, also known as Avastin, is a drug which is made by 
the company Genentech. Bevacizumab is a humanized monoclonal 
Anti- Vascular Endothelial Growth Factor (VEGF) antibody that 
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blocks all three isoforms of VEGF-A and blocks interactions with 
the VEGF R2 receptor. VEGF expression in GB and recurrent GB 
is associated with vascular permeability, tumor cell proliferation, 
and tumor cell migration. 
 
     
Schematic 1.1: Blockage of VEGF Signaling Cascades by 
Avastin (Made through Biorender) 
Schematic 1.1 illustrates the pathways that become active, both 
PI3K/AKT and RAF/MEK/ERK1/2, to promote vascular 
development for the tumor and increase proliferation of tumor cells. 
Ligand VEGF-A, the ligand that typically binds to the VEGF R2 
receptor, has other roles involved in activating migration and 
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proliferation of endothelial cells (ECs) to maximize angiogenic 
capacity of the tumor microenvironment. Abundance of VEGF-A 
growth factor creates a gradient of soluble chemo attractants for 
endothelial cells to migrate towards.8 VEGF inhibition has the 
potential to be moderately dangerous to certain patient subsets, 
and recent evidence demonstrates that Anti-VEGF mAb inhibition 
leads to problems such as nephrotoxicity and can be deadly to 
patients.9 VEGF is an essential growth factor to promote 
angiogenesis  and healthy functioning of blood vessels. Thus, there 
is a necessity to look at other forms or methods to target cancer’s 
highly immunosuppressive immune environment. 
Chapter 2: Review of the Literature  
     This chapter will discuss the current literature in the field of 
Glioblastoma and general cancer research by examining 
mechanisms of Recurrent Glioblastoma, current trend in cancer 
therapeutics, Galectin-1 in cancer progression and 
immunosuppression, the role of both hypoxia and radiation in the 
TME and describe why our therapeutic approach is innovative.  
Mechanisms of Recurrent Glioblastoma 
     Many different cellular and extracellular mechanisms play a part 
in establishing resistance to treatment for recurrent GB. Cancer 
stem cells (CSCs) in the tumor have properties that lead to 
7 
 
adaptation and response to the microenvironment and treatment 
methods. CSCs are referred to as tumor initiating cells due to their 
high capacity to generate tumors in xenograft models.10-11 CSCs for 
GB are derived from neural stem cells and are believed to be the 
driving factors that lead to the genetic diversity encompassing the 
tumor. Cancer researchers have a consensus that cancer stem 
cells are what drives resistance and recurrence. The common 
marker for CSCs is CD 133.12 Recurrent Glioblastoma is 
challenging to make effective therapeutics for due to its strong 
drug-resistance through hypoxia and vast expression of CSCs, 
immunosuppression, and similarities to tissue necrosis due to 
irradiation. 
    Recurrent GB cells gain a further capability for drug suppression. 
Initial GB naturally has small amplitude of drug suppression 
capacity due to inefficiency of drug deliver. The previously 
discussed blood brain barrier limits the quantity of treatment that 
gets to the targeted tumor in the brain. There is no efficient way of 
direct targeting removal of the entire tumor due to the stress that 
additional surgery will have on the brain and the potential disruption 
of the glymphatic system. Recent evidence illustrates that there is a 
small set of cancer cells within the tumor that are named persisters 
due to their relative similarity to colonies in E.coli culture that are 
persistent to antibiotic treatment.13 These cancer persister cells 
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gain drug-tolerant capabilities through mechanisms of either 
chromatin or metabolic remodeling.13 Evidence has shown that 
treatment resistance for GB can derive from gene mutations and 
slow growing cancer persister cells after long term treatment with 
TMZ.14 The metabolic, cell survival, and epigenetic changes that 
occur in cancer persisters are in response to slow cell growth 
characterized by the environment.15 Along with cancer persisters, 
cells have proteins that are transporters that pump the attempted 
treatments out of the tumor. 
     ATP binding cassette (ABC) transporters are efflux transporters 
that pump out different chemotherapeutics. Analysis of their 
expression can help guide the understanding of multiple drug 
resistance (MDR) in multiple cancers and patients . ABCB 1, a 
specific ABC transporter protein, has many different drugs that act 
as a substrate but the major one is TMZ.16 Expression of this 
protein indicates that the GB will be less responsive to the standard 
of care and have a high potential to reoccur. These ABC 
transporters and their expression may be increased in recurrent GB 
and that is why they are less likely to have a response to treatment. 
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Schematic 1.2: Major Players of Immunosuppression in 
Glioblastoma (Made through Biorender) 
     The tumor microenvironment in GB and recurrent GB is highly 
immunosuppressive and suppresses anti-tumor activity led by 
immune effector cells. There is an increase in regulatory T 
lymphocytes (Tregs) in the tumor microenvironment (TME) and 
peripheral blood. Immunosuppression is mediated by heightened 
amounts of Tregs expressing FoxP3 in the peripheral blood which 
inhibits immune responses and antitumor activity.17-23  The increase 
in circulating Tregs reduces the amount of cytotoxic CD 4+ and 






     The CDC stated statistics that illustrate that Cancer is still the 
second highest cause of death in the United States. Treatment is 
still ineffective and new methods are being created, brought into 
clinical trials, and advancing to the clinical setting. The push 
towards advancing therapy lies in methods of CAR-T therapy, and 
specifically targeted antibodies. CAR-T therapy has had proven 
success with blood cancers but has not been looked at extensively 
at other cancers. It would not work in the brain due to unknown risk 
with interactions of neurons and how it could modulate cognitive 
and motor function. The other form of advancement comes in 
target-specific antibodies. These antibodies look at targeting a 
specific protein or activating an immune response to attack the 
tumor.  
Table 1:1- Approved Antibodies for Treatment of Cancer (Cancer 
Research Institute) 
Table 1:1 illustrates the current approved monoclonal antibodies 
that target specific pathways that are promoted in cancer to 
Drug Trademark Name Target Disease
Alemtuzumab Campath CD 52 Leukemia
Bevacizumab Avastin VEGF Brain, cervical, colorectal, kidney, liver, lung, and ovarian cancer
Cetuximab Erbitux EGFR Colorectal cancer and head & neck cancer
Daratumumab Darzalex CD 38 Multiple myeloma, colorectal, esophageal, liver, lung, & stomach cancer
Rituximab Rituxan CD 20 Leukemia and Lymphoma
Tafasitamab Monjuvi CD 19 Lymphoma
Trastuzumab Herceptin HER 2 Breast, espohageal, and stomach cancer
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increase cell proliferation and cell migration. As shown by the chart 
the only one approved for glioblastoma, the brain cancer, is 
Avastin. This chart demonstrates that there is a need to develop 
more therapeutic options for glioblastoma. Further looking into 
other pathways and mechanism of targets to block could improve 
the efficacy of treatment and provide patients with more options 
tailored to their medical needs.  
Galectin-1’s Role in Cancer and Immunosuppression  
    Galectin-1 (Gal-1) is a lectin which is a carbohydrate binding 
protein that has a high affinity for binding β- galactosides. The 
composition of the protein includes two subunits of a total size 
of14.5 kDa (135 aa) that reside in a dynamic dimerization 
equilibrium.24 Gal-1’s structure is influenced by 2 anti-parallel β-
sheets with a conserved topology of a carbohydrate recognition 
domain.25 Gal-1’s CRD contains a high affinity to bind LacNAc-
bearing structures via van der Waals interactions and hydrogen 
bond formation.25 The binding is mediated by key amino acids that 
include His45, Asn47, Arg49, Val60, Asn62, Trp69, Glu72, and 
Arg74.25 Gal-1 is considerably upregulated and overexpressed in 
inflammatory macrophages, immunosuppressive DCs26-28, activated 
T and B cells29-30, CD4+CD 25+ Tregs and uterine NK cells31-32. 
Gal-1 regulates the immune effector cell populations previously 
stated by interactions with properly glycosylated  cell receptors that 
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include CD 45, CD 43, CD 3, CD 2, CD 4, CD 7, CD 69, and pre-B 
cell receptor (pre-BCR).33-40 Through cellular interactions stated in 
paragraphs below, Gal-1 has emerged as a novel regulatory 
checkpoint that positively influences immune evasive programs of 
cancer cells’ by inducing T-cell exhaustion, limiting survival of T-
cells, favor an expansion of regulatory T-cells, de-activate natural 
killer (NK) cells, and polarize myeloid cells towards an 
immunosuppressive phenotype.24 Gal-1 has many implications in 
adaptive and innate immunity. Attached to the cell membrane Gal-1 
selectively promotes apoptosis of Th 1 and Th 17 cells41, induces Il-
10 secretion42-45, inhibits T-cell trafficking46and decreases nitric 
oxide (NO) production by macrophages.47-48 
    Gal-1 alters T-cells viability by creating disruptions that promote 
apoptotic factors and limit efficiency of TCR signal transduction. 
The Gal-1 receptors CD 3, CD 4, CD 2, CD 45, GM1, and CD 43 
impact TCR signal transduction through reorganization at opposite 
poles during synaptogenesis and distal pole complex formation.37-
40,49-51 The lectin’s immunoregulatory capabilities may result from its 
capacity to modulate TCR signal transduction, T-cell synaptic 
organization, and T-cell polarity. Gal-1 also acts as a TCR 
antagonist and limits sustained TCR signaling during continued CD 
8+ T-cell activation.52 Gal-1 acts as an autocrine negative 
regulatory of CD 8+ burst size and provides concrete identification 
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of modulation of the TCR ligand binding in time of T-cell 
activation.52 Gal-1 regulates CD 8+ and CD 4+ T cell populations 
while increasing the percentage of regulatory T-cells (Tregs). The 
protein engages with the receptor CD 45 and instructs the T-cell to 
a regulatory T-cell signature which is characterized by high Il 10 
and Il 21 expression.53 Gal-1 modifies the c-Maf/aryl hydrocarbon 
receptor pathway in these instances. 53 Gal-1 alters T-cell fate and 
promotes apoptotic factors for eventual T-cell death. Gal-1 
mediated cell death transpires independent of caspase activation  
by nuclear translocation of mitochondrial endonuclease G which is 
not accompanied by cytochrome C- release.54 Gal-1 mediates t-cell 
viability by selectively deleting through apoptotic or TCR disruption 
in CD8+ and CD 4+ cells while simultaneously increasing the 
populations of TREGS. Gal-1 induces apoptosis in CD 8+ and CD 
4+ t cells through disruption of TCR signal transduction, while 
increasing TREGS which induce expression of Il-10 and Il-21 
expression activating a M2 phenotype in macrophages and 
promoting an anti-inflammatory response in the immune effector 
cell populations. These mechanisms lead to a heightened 
immunosuppressive environment for the cancer to thrive in and 
grow undetected. 
         Cancers promote a tumor microenvironment that is highly 
hypoxic and lacks adequate oxygen supply.  Recent findings 
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suggest hypoxia increases the amounts of b1-6GlcNAc-branched 
N-glycans and poly-LacNAc structures, reduces a2-6 sialylation, 
and induces slight changes in asialo-core-1 O-glycans in 
comparison to normal healthy oxygen conditions55 Refractory 
tumors occur even in the presence of treatment with Anti-VEGF 
mAb and in these instances Gal-1 expression increased. The 
recent findings showed that Gal-1 maintained activation of VEGF 
activated angiogenesis and proliferation pathways through over-
expression phospho Akt (Thr308), Akt (Ser473), and Erk1/2.55 
Overexpression of Gal-1 reduces sensitivity to Anti-Vegf treatment 
by keeping the PI3K-AKT-MTOR and Ras-Raf-MEK-ERK pathways 
open. Gal-1 keeps these pathways open by interactions with 
VEGFR2 through N-glycosylation-dependent mechanisms.55 These 
studies show that not only is Gal-1 promoting an anti-inflammatory 
response in the tumor microenvironment, but Gal-1 is also keeping 
angiogenesis and proliferation pathways active through complex N-
glycan interactions with cell surface receptors like VEGF-A. 
Schematic 1.3. is below to help illustrate the binding of VEGF by 




Schematic 1.3. Galectin-1 Complex N Glycan Branching to VEGF 
(Made through Biorender) 
Role of Hypoxia in the Tumor Microenvironment 
     Hypoxia plays a critical role in helping to establish tumor 
angiogenesis and helping to create a tumor microenvironment that 
favors the metabolic switch of cancer cells from oxidative 
phosphorylation to anerobic glycolysis. Hypoxia inducible factor 1 
(HIF-1) is made up of two subunits, HIF-1α and HIF-1β. HIF-1α is 
oxygen dependent and in normal conditions hif-1 α is degraded by 
the proteosome by being marked with a hydroxyl group (OH) for 
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degradation by proline-hydroxylase-2 (PHD-2) and by vonHippel-
Lindau (VHL)-ubiquitin ligase complexes.56-57 As tumor cells 
proliferate limiting the quantity of oxygen in the microenvironment, 
hif-1 α stabilizes and is no longer marked and degraded. Hif-1 α 
stabilization leads to binding of Hif-1α to Hif-1β generating the Hif-1 
complex. The Hif-1 complex binds to the binding site which consist 
of the core sequence 5’-CGTG-3’ of the hypoxic response element 
(HRE) domain that sits on regulatory regions of target genes to 
activate expression. Over 70 known genes that play roles that 
include angiogenesis, cell proliferation, apoptosis, and cell 
stemness are transcriptionally regulated by Hif-1 complex.58  
Activation of the complex leads to an increase in VEGF expression 
supporting angiogenesis and the reduction of oxygen in the 
environment making treatments such as chemotherapy and 
radiation less successful at attacking GB.  
Role of Radiation in Cancer 
    Radiation is a treatment technique that has been used since the 
advancement of science and computer technology. Through 
molecular biology techniques radiation has been shown to cause 
single and double strand breaks in DNA which can leads to signals 
of apoptosis and cell senescence. Radiation decreases oxygen in 
the microenvironment leading to an increase in HIF-1 activity and 
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Gaining knowledge from studying human tumor samples, 
specifically GB, is essential to further understanding of the 
environment and protein expression through the tumor. Our lab has 
access to human samples that we can analyze, and it gives us a 
capacity to analyze if certain treatment methods are worth 
pursuing. Previous research indicates Gal-1 plays a role in helping 
establish an immunosuppressive tumor environment and leads to 
progression of cancer. The purpose of these experiments, Gal-1 
expression profiling and tumor staining, was to gain a better grasp 
on the tumor microenvironment and characterize Galectin-1 
expression in patient samples. High Gal-1 would validate the 
notions that this protein plays some sort of role in GB and that it is 
worth being investigated as a potential therapeutic target. 
Materials and Methods 
Human samples were supplied through a Neurosurgeon that is in 
our department (Department of Neurosurgery). The samples were 
placed on ice and were immediately placed in -80°C freezer until 
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further use. All collection methods followed approved IRB protocols. 
Western Blot 
Tissue was cut into smaller pieces with scalpel and suspended in 
500 µl of Homogenizing Buffer (2 mM EDTA, 50 mM Tris-Cl (pH 
7.5), 0.5 mM DTT)(dithiothreitol)). Tissue was sonicated and 5µl 
was pipetted and placed in a glass vial filled with 1ml of DI water. 
After that step, the glass vial was filled with 1ml of Coomassie 
assay buffer and vortexed. 200µl was placed in a 96-well plate 
reader along with standards of 0, 2, 5, 10, 20, and 40 µg of BSA 
(concentration 1µg/µl) and the plate was read at 495 nm. Protein 
content was calculated, and tissue was diluted to 1µg/1ml with 500 
µl of Sample Buffer  and Homogenizing Buffer + Sample Buffer + 1 
% HB+SB Bromophenol. The tubes were stored in -80°C freezer 
until was ready to use. 
Tubes were taken out of freezer and placed in warm water. The 
tubes were then vortexed. Bio-rad Pre-cast TGX 4-15% 
Tris/Glycine Page Buffer 15 well (15µl) were placed in a 
electrophoresis chamber filled with SDS running buffer. Each well 
was filled with 7.5 µl of specific human sample protein, and the 
system ran at 125 volts for 1.5 hours. Once the protein ran to the 
end of the gel, it was placed on a PVDF membrane sandwiched 
between to filter papers between sponges that were soaked in 
Transfer buffer. The PVDF membrane in the Transfer buffer was 
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ran at 12 volts for two hours. After this the membrane was removed 
and placed in a blocking solution of 2% non-fat milk in TBST. The 
membrane was blocked for 1 hour, then the blocking buffer was 
discarded and replaced with primary antibody at a concentration of 
(1:2,000) in 2%non-fat milk TBST. The membrane was incubated 
overnight at 4°C. After incubation, the primary antibody solution 
was discarded and saved for further Western Blots. The membrane 
was washed three times with TBST for 12 minutes each. TBST was 
discarded and the membrane was placed in the secondary antibody 
(1:5000) 2 % non- fat milk TBST solution. The secondary antibody 
used is dependent upon the primary antibody. The secondary 
antibody was discarded after an hour of incubation at room 
temperature. The membrane was washed in TBST and then taken 
to a Chemi Doc imager. ECL was prepared by adding equal 
solutions of solution A and solution B to a 15 ml tube wrapped in 
tinfoil to cover it from light. 1 ml of ECL was placed on each 
membrane once placed an imager. Image was saved to flash-drive 
for data- analysis. 
Cryostat Sectioning 
Tumor samples were sliced into small pieces using a scalpel and 
one small piece was taken and placed in tissue freezing medium 
(TFM) and allowed to freeze in the medium in the -80° freezer. 
Once ready the frozen TFM and tissue were mounted on a cryostat 
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specimen chuck. The tissue was sliced at an approximate width of 
12 µm and tissues were placed on Fisher Brand Super frost Plus 
pre cleaned slides. Slides were correctly labeled and stored in -
80°C freezer until ready to go through immunofluorescence 
staining.  
Immunofluorescence Staining 
Slides are taken out of the -80° C freeze and allowed to come to 
room temperature by incubating for 45 minutes to an hour. Then 
slides are immersed in 95% EtOH for 10 min followed by two 
washes in PBS (1X) for 2.5 minutes each. The slides are moved to 
a solution of 4% paraformaldehyde dissolved in PBS (1X) where 
they are immersed for 15 minutes followed by three washes with 
PBS (1X) for 2.5 minutes each. Following the washes with PBS 
(1X) the slides are immersed in 0.2% Triton X-100 dissolved in PBS 
(1X) for 5 minutes followed by another three washes of PBS (1X) 
for 2.5 minutes each. 100µl/slide of 4% serum in PBS(1X) is 
applied to each slide for an hour for blocking. The serum is 
dependent upon the species of the secondary antibody. In our 
experiments the secondary antibody is goat, so the serum is 4% 
goat serum in PBS (1X). The 4% goat serum in PBS (1x) is wiped 
away from the edges not touching the tissue by a Kimwipe, then 
100µl of the primary antibody(1:500 dilution) is applied to each slide 
for 2 hours at RT followed by three washes of PBS (1X) at 2.5 
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minutes each. After the three washes with PBS (1X), 100µl per 
slide of secondary antibody (1: 500 dilution) in 4% goat serum in 
PBS (1X) is applied to the slides for 1 hour at RT. Application of the 
secondary antibody and the following steps must occur in the dark. 
Ensuing secondary antibody incubation, the slides are washed 
three times with PBS (1X) at 2.5 minutes each. Kim wipes are used 
to dry the edges around the tissue in the slides and a plastic 
Pasteur pipette is used to incorporate 1-2 droplets of Vectashield+ 
Dapi onto the slides. Cover slips follow this process and are placed 
over the mounted stained tissue. Slides can be kept for 2-3 days 
and are imaged using an Olympus. 
Statistical Analysis 
For IHC staining 12 images were taken with each of the constraints 
that were ROS 1 positive and ROS 1 negative. Western Blots 
conducted included 10 samples for each of the patients and 10 
samples for the normal brain tissue which was taken from healthy 
individuals with no current state of mental disease or disorder. Data 
illustrated in this thesis for human patient samples illustrates the 
expression conserved through multiple exposure of analysis from 







Image 3.1: Staining and Expression Analysis of GB Patient 
The sample size for the staining and western blots was 20 patients 
and the normal tissue analysis was 12 patients. There were 12 
images taken from each patient for the IHC of Ki-67, GFAP, and 




The results indicate that Gal-1 is overexpressed in GB patients. 
This overexpression leads us to conclude that Gal-1 must play a 
role in establishing the tumor and the tumor’s microenvironment to 
prevent effective treatment. Immunofluorescence staining of the 
tissue indicates that the GB tumors have an extremely high rate of 
proliferation (Ki-67), and expression of Glial fibrillary acidic protein 
(GFAP). GFAP is a commonly used marker to get an understanding 
of the severity of the tumor. The analysis of human samples drives 
our lab to look further into Gal-1 expression by conducting various 
in vitro and in vivo assays. Our next steps will be to understand 
Gal-1 expression in endothelial cells and test its feasibility as a 
therapeutic through in vitro drug assay methods. 
Chapter 4 
Introduction 
From analysis of Glioblastoma patients there was an increase in 
Gal-1 expression compared to healthy tissues. These results 
indicated that this protein has some sort of role in supporting tumor 
growth. The goal of these experiments was to validate Gal-1 
inhibition as a potential treatment in an in-vitro model while 
comparing it to VEGF inhibition and in conjunction with VEGF 
inhibition. The second goal of the experiments was to design a co 
culture system with GB cells and HUVEC cells. Previous literature 
suggest that Gal-1 has strong roles in the extracellular matrix 
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(ECM) and endothelial cells. Gal-1 may act similarly to VEGF in 
increasing endothelial cell proliferation leading to increased 
angiogenesis that supports tumor function and growth. These 
experiments aim to answer these questions and provide more 
background into relationships Gal-1 has with different factors of 
Glioblastoma.  
Materials & Methods 
In-vitro Drug Treatment of GB Cells 
The Glioblastoma cell lines, 43 RG 32 28 24 which were given to us 
by the Cleveland Clinic, were either not treated or treated with 
Bevacizumab, OTX 008, or Bevacizumab + OTX 008. Cells were 
grown until approximately 70% confluency in the flask until 
treatment started. The combinational treatment of Bevacizumab + 
OTX 008 started with treatment of Bevacizumab on the first day 
followed by OTX 008 on the 2nd day. On the 5th day cells were 
scraped from the flask and inserted into a 15ml conical tube with 10 
ml of media. The cells were spun at 5,000 rpm for 5 minutes, and 
the media was discarded, and the cells were frozen in -80°C 





A MTT solution was created at a concentration of 5mg/ml dissolved 
in PBS. Preparation of MTT solvent was created with 4 mM HCl, 
0.1% NP40 in isopropanol. Cells were scrapped from 75cm3 and 
spun at 4,000 g for 5 min. Then supernatant was poured off and the 
cells were suspended in 100 µl of serum free media. After 
suspension 50 µl of cells + serum free media were pipetted into the 
96 plate well. 50 µl of MTT was placed in each well. The 96 well 
plate was incubated for 3 hours at 37 ºC. Add 150 µL of MTT 
solvent into each well. Wrap plate in foil and shake on an orbital 
shaker for 15 minutes. Read absorbance at OD=590 nm.  
Western Blots                                                                               
Cells were lysed and protease inhibitors were utilized. Cells were 
suspended in 100 µl of Homogenizing Buffer (2 mM EDTA, 50 mM 
Tris-Cl (pH 7.5), 0.5 mM DTT)(dithiothreitol)) After suspension cells 
were transferred to tubes with correct labeling. The suspended cells 
were sonicated. Glass tubes were filled with 1 ml of deionized (DI) 
water, 5 µL of suspended protein+ HB, 1ml of Coomassie assay 
buffer, and then vortexed. 200 µl of solution from the glass tube 
was taken and plated on a 96 well plate. The standards for the 
Bradford Assay were 0,2,5,10,20,40 (µg/µl) BSA duplicated and 
plated. Two solutions of 200µl were taken from each glass tube and 
then averaged and calculated to make 1µg/ 200µl solutions with 
HB+SB (Bromo-phenol) added for purpose of western blots. Gels 
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were loaded and run at an hour and half at 100 volts. The gels were 
then sandwiched between a PVDF membrane and two membrane 
filters and placed in transfer buffer and run at 12 volts for two hours. 
Then membranes were placed in blocking buffer (2% non-fat milk in 
TBST)  for one hour. Then the selected primary antibody was 
diluted 1:2,000 in 2%  non- fat milk TBST. The blocking buffer was 
discarded and the membranes were placed in the primary antibody 
cocktail overnight at 0 to -4°C on a shaker. The next day the 
membranes are allowed to come near room temperature then are 
discarded and washed three times for 12 minutes with TBST. After 
that the membranes are placed in a secondary antibody cocktail 
that includes the selected secondary antibody at a concentration 
ranging from 1:5,000-1:8,000 in 2% nonfat milk and TBST. The 
membranes are incubated at room temperature for an hour. The 
membranes are washed another 3 times with TBST and then are 
ready to be imaged by a Bio-Rad ChemiDoc imager. Membranes 
are pulled from their containers one by one and drained of TBST 
and placed on the screen of the imager. ECL is prepared ahead of 
time with equal parts of solution A and solution B. 1.5 of ECL 
reagent is pipetted on the membrane, and then the membrane is 
imaged for protein expression of selected primary antibody. 
Caspase 3 Assay 
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Cells that were undergoing treatment were lysed and protein 
estimation calculations (Bradford Assay) were conducted. 
Approximately 250µg of protein of each sample were taken for use 
in the caspase 3 colorimetric assay (Sigma Aldrich). The  microliter 
quantity that gave 250µg of protein was taken for each sample and 
placed in the specific well. The cell treatments calculated came 
from triplicate of the treatments conducted. After the cell lysate was 
placed in the specific wells, 980µl of 1x Assay Buffer was added to 
each well. The Assay Buffer was formed by diluting 10x assay 
buffer to the correct volume with the 17 megaohm water provided in 
the kit. 10µL of Caspase 3 substrate was then added to well. The 
caspase 3 substrate was dissolved in DMSO and diluted in 1x 
assay buffer to bring the Caspase 3 substrate from 20mM down to 
2 mM. The plate was then covered and incubated at 37°C 
overnight. The next day the absorption of the plate was run at 405 
nm.  
Co-Culture Proliferation Assay with Bevacizumab 
Co-culture assays helped to establish the role of Galectin-1 as a 
factor similar to VEGF in its promotion of angiogenesis. For the co-
culture the bottom layer of cells on the system were Human 
umbilical vein endothelial cells (HUVEC) and the system was set up 
once the HUVEC reached approximately 20,000 cells. The number 
of cells was validated through cell counting on a hemocytometer. 
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The cells were counted 3 times at each day indicated with the 
experiment run in triplicate. P values did not exceed .05. The 
glioblastoma cell line was plated on a 0.4µm filter system position 
above the endothelial cells. Schematic 3.1 shows the set up of the 
co culture system. Once the Glioblastoma cells were plated on the 
porous filter membrane and were treated either with either no 
treatment, dose of Bevacizumab, or dose of Bevacizumab and 
OTX008. Following this treatment of the Glioblastoma cells, the 
quantity of HUVEC is counted at the intervals of initial (0 days), 3 
days, 7 days, and 10 days. Counting was done through trypan blue 
dying for cell viability and counted with the utilization of the square 
system of the hemocytometer. The three constraints of treatment 
methods went as follows: untreated, Bevacizumab, and 
Bevacizumab+ OTX008. There were 4 co culture systems of each 
treatment method to be able to effectively count cells at 0, 3, 7, and 
10 day periods. After treatment was finished. Cells were blocked 
with protease inhibitors and lysed to run Westerns to look at 
Galectin-1 expression.  
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Schematic 4.1: Treatment of Bevacizumab in Glioblastoma Cells 
Co Cultured with Endothelial Cells 
Co-Culture Proliferation Assay with Radiation  
A co-culture assay was set up in a similar style to that of the 
previously describe co-culture with Bevacizumab treatment, but this 
time focusing on radiation. Scientific literature shows mixed reviews 
on the influence of radiation in cancer. Previous research indicates 
that radiation, more specifically higher doses of radiation lead to 
healthy cells and tissue surrounding the tumor  turning into necrosis 
which allows for tumor growth and helps in making a larger barrier 
to thwart treatment options. This study was done to further develop 
and comprehend the relationship between radiation and Gal-1 
expression. Glioblastoma cells were grown and plated on a 0.4µm 
porous membrane that was placed in a proximity dependent 
manner above the endothelial cells. The endothelial cells were 
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plated before the Glioblastoma cells on the bottom of the petri dish 
at a population of approximately 20,000 cells. 6 gy of radiation was 
given consecutively (3 times total) after 72 hours of the co culture 
being in place. The treatment constraints were untreated, radiation, 
radiation and OTX008 together. Endothelial cells were stained with 
trypan blue to validate cell viability and counted utilizing a 
hemocytometer. Endothelial cells had protease inhibitors added 
and cells were lysed through sonication for purpose of protein 
estimation and Western Blot analysis.                                                                                                                                
Schematic 4.2: Treatment of Glioblastoma Cells with Radiation Co 
cultured with Endothelial Cells                                                                                            
Cell Counting with Hemocytometer     
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The goal of the co-culture assays is to analyze different treatment 
options and their influence on angiogenesis by looking at 
endothelial cell proliferation. Endothelial cells must be counted to 
effectively analyze their characteristics in the presence of 
treatment. The device used is called a hemocytometer and has little 
grid like squares that can be utilized for a full estimation of the cell 
count for different subsets. The cells were counted 3 times each 
where n=3. By having 9 counts of cells it gives a better estimation 
of cell count through the triplicate of experiments conducted. 
Statistical Analysis 
All studies conducted are at constraints where n is greater than or 
equal to three. For cell proliferation assays, cell counts were 
conducted three times for each time point and the Glioblastoma cell 
co culture with endothelial cells was at n is greater than or equal to 
three. Each of the figures indicates the values calculated between 
time points and multiple stages of data collection. The percentage 
of standard of error for cell counting did not exceed .05 for any of 
the constraints.  
32 
 
                                                                                                                                    
Results 
Image 4.1 Gal-1 Expression in Bevacizumab Treated Co-Culture   
 
 





























Image 4.6  Western Blot Analysis 
Discussion 
The results indicate that there is an increase in apoptotic activity 
(Caspase 3 assay) and decrease in cell viability (MTT) assay with 
regards to Vegf inhibition (Bevacizumab), gal-1 inhibition (OTX 
008), and a combination of Vegf + gal 1 inhibition (Bevacizumab + 
OTX 008). The sharpest decrease comes in the form of the 
combinational treatment, indicating that it might be the most 
feasible way to reduce the functionality of the tumor cells. At the 
same time Gal-1 expression is influenced by common treatment 
methods that are generally given in the clinic for either GB or 
recurrent GB. Both co culture assays with Bevacizumab and 
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radiation showed a sharp increase in Gal-1 compared with the 
control. These increases amounted to approximately 18-24% in 
both cases. These results specify Gal-1 expression and the 
alteration of Gal-1 expression that takes place in blood cells. A 
direct correlation was portrayed by Gal-1 expression and 
endothelial cell proliferation in response to treatments. This direct 
correlation has the potential to be a mechanism that tumors 
incorporate to keep vasculature and promote angiogenesis even in 
the presence of treatment. From this data, we decided to go a step 
further and investigate the response to a mouse glioblastoma cell 
line injected into a C57BL6/J mouse.  
Chapter 5 
Introduction  
The goal of this study was to look deeper at the potential of Gal-1 
inhibition with or without conjunction  of VEGF inhibition. The in-
vitro studies drug studies were for validation of the concept of Gal-1 
as a potential therapeutic target. The next step was to look at the 
potential therapeutic or combinations of the potential therapeutic for 
the treatment of GB in a relevant mouse model. Mouse models 
provide further validation of therapeutic success due to their more 
realistic stimulation. For the mouse, you have a similar 
microenvironment that holds microglia, astrocytes, and similar 
neuronal structure to the human brain. This method of 
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experimentation gives a better indication of the effectiveness of the 
therapeutic.  
Materials and Methods 
Schematic 5.1: Experiment Design of Mouse Model 
 
Gl 261 (mouse glioblastoma cell line) were grown to 30% 
confluency. Cells were washed three times with PBS and then 
centrifuged at 5,000rpm for 5 minutes. Following that cells were 
suspended in 5 µl of PBS, and ready for use of injection.  
Bevacizumab Recurrent Model 
The Bevacizumab recurrent model had a slightly different timepoint 
then the previous described schematic and detail of the mouse 
Glioblastoma model. The Alzet mini pump was placed in the same 
time period shortly after implantation of the Gl 261 tumor cells. Anti-
VEGF therapy started immediately on the first day. After 14 days 
Magnetic Residence Imaging (MRI) was conducted on the mice for 
verification of tumor. Only the mice with validation of tumor growth 
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were selected for treatment with OTX 008 and the bed of the Alzet 
mini pump was replaced with OTX 008. The goal of these studies 
was to see the feasibility of Gal-1 inhibition in a relevant 
Bevacizumab recurrent model.  
Dissection of Brain 
Mice were sacrificed following survival analysis. After animal 
sacrifice surgical scissors were used to cut through the skin 
covering the skull, and then used to cut the skull posterior to 
anterior to give a clear image of the brain. The brain was then 
gently pulled out of the mice to give a clear path to cut the 
connection of the spinal cord to the brain. From this point a scalpel 
was used to cut the connection, and brains were labeled 
appropriately in tinfoil boats. The tinfoil boats were filled with tissue 
freezing medium to protect the genetic profile of the brain and 
stored at -80°C for later use. 
Cryostat Sectioning 
The brains defrosted for 5 minutes before specimens were 
mounted on a specimen chuck. The brains were mounted in a 
manner shown by schematic 5.2 below. The schematic shows that 
mounted occurred posterior to anterior with cerebellum facing up 
and being the first part to be sliced. Contact with the tumor began 
shortly after finishing slicing cerebellum. Slices were collected on 
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permafrost glass slides and stored at -80°C freezer until staining 
protocols started. 
Antibodies, Microscope, and Software  
Table 5.1 Antibodies used for Staining. 
 
Table 5.1 is meant to identify the types of primary and secondary 
antibodies used for the purpose of IF imaging. The device used for 
the imaging is the Olympus DP 80 multicolor image camera 
attached to a confocal microscope. The set up is inverted with the 
tissue slides placed face down for imaging. The software used to 
image and quantified the pixel area for the fluorescence excitation 
is cellSens by Olympus. Three images were taken on each brain 
with 10 tumor slices per brain. The pixel area of the fluorescence 
excitation was calculated as along with the standard deviation.   
Immunofluorescence Staining  
Slides are taken out of the -80° C freeze and allowed to come to 
room temperature by incubating for 45 minutes to an hour. Then 
slides are immersed in 95% EtOH for 10 min followed by two 
washes in PBS (1X) for 2.5 minutes each. The slides are moved to 
Primary Antibody Secondary Antibody
Santa Cruz CD 133 Rabbit pAb Abcam Goat pAb to Rabbit Alexflour 488
Sigma Hif-1α rabbit mAb Abcam Goat pAb to Rabbit Alexflour 489
Abcam Ki-67 rabbit mAb Abcam Goat pAb to Rabbit Alexflour 490
Abcam Galectin 1 rabbit mAb Abcam Goat pAb to Rabbit Alexflour 491
Sigma VEGF-A rabbit pAb Thermo Scientific Goat Anti Rabbit Dylight 594
Mtl International Survivin rabbit pAb Abcam Goat pAb to Rabbit Alexflour 493
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a solution of 4% paraformaldehyde dissolved in PBS (1X) where 
they are immersed for 15 minutes followed by three washes with 
PBS (1X) for 2.5 minutes each. Following the washes with PBS 
(1X) the slides are immersed in 0.2% Triton X-100 dissolved in PBS 
(1X) for 5 minutes followed by another three washes of PBS (1X) 
for 2.5 minutes each. 100µl/slide of 4% serum in PBS(1X) is 
applied to each slide for an hour for blocking. The serum is 
dependent upon the species of the secondary antibody. In our 
experiments the secondary antibody is goat, so the serum is 4% 
goat serum in PBS (1X). The 4% goat serum in PBS (1x) is wiped 
away from the edges not touching the tissue by a Kimwipe, then 
100µl of the primary antibody(1:500 dilution) is applied to each slide 
for 2 hours at RT followed by three washes of PBS (1X) at 2.5 
minutes each. After the three washes with PBS (1X), 100µl per 
slide of secondary antibody (1: 500 dilution) in 4% goat serum in 
PBS (1X) is applied to the slides for 1 hour at RT. Application of the 
secondary antibody and the following steps must occur in the dark. 
Ensuing secondary antibody incubation, the slides are washed 
three times with PBS (1X) at 2.5 minutes each. Kim wipes are used 
to dry the edges around the tissue in the slides and a plastic 
Pasteur pipette is used to incorporate 1-2 droplets of Vectashield+ 
Dapi onto the slides. Cover slips follow this process and are placed 
over the mounted stained tissue. Slides can be kept for 2-3 days for 
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optimal imaging at 4°C or -80°C for longer storage and are imaged 
using an Olympus microscope. 
Results 
Image 5.1 Ki-67 Cell Proliferation Analysis: Mouse Samples 
 





Image 5.3 VEGF-A and Gal-1 Expression Analysis: Mouse 
Samples 
 
Image 5.4 Survivin Apoptotic Activity Analysis: Mouse Samples 
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Image 5.5 Hif-1α Hypoxia Analysis: Mouse Samples 
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Ki-67 Pixel Area µm squared Standard Error (%)
No treatment 1410.25 0.0017
OTX008 659.2 0.0027
Bevacizumab 904.28 0.0025
OTX 008+ Bevacizumab 402.63 0.0116
Recurrent Bevacizumab + OTX 008 1137.56 0.0066
Survivin
No treatment 1347.42 0.0050
OTX008 910.16 0.0060
Bevacizumab 1012.23 0.0086
OTX 008+ Bevacizumab 342.43 0.0073
Recurrent Bevacizumab + OTX 008 1218.67 0.0061
CD 133
No treatment 2063.32 0.0055
OTX008 254.81 0.0327
Bevacizumab 609.27 0.0201
OTX 008+ Bevacizumab 78.86 0.0153
Recurrent Bevacizumab + OTX 008 128.82 0.0059
Hif-1 α
No treatment 1085.1925 0.0021
OTX008 463.27 0.0089
Bevacizumab 527.86 0.0080
OTX 008+ Bevacizumab 109.87 0.0219
Recurrent Bevacizumab + OTX 008 210.78 0.0108
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Table 5.3 Gal-1, VEGF-A, & Co-localization between VEGF-A and 
Gal-1 Immunofluorescence Pixel Area (µm2) 
 
Discussion 
Staining allows for imagery in science which can be novel and help 
piece together relationships of various factors between different 
treatment methods. The goal of these stains was to visualize 
hypoxia, cancer proliferation, cancer stem cell populations, VEGF-
A, Gal-1, and anti-apoptotic activity across the treatment groups of 
no treatment, Gal-1 inhibition through OTX 008, VEGF inhibition 
through Bevacizumab, a combination of the two, and a recurrent 
VEGF model. Ki-67 showed a vast proliferation in untreated and 
recurrent GB. There were similar expressions of Ki-67 in 
Pixel Area µm squared Standard Error (%)
Gal-1
No treatment 347.81 0.0189
OTX008 128.61 0.0172
Bevacizumab 278.41 0.0161
OTX 008+ Bevacizumab 28.27 0.0258
Recurrent Bevacizumab + OTX 008 4.63 0.0518
VEGF-A
No treatment 420.26 0.0177
OTX008 807.23 0.0128
Bevacizumab 694.2 0.0133
OTX 008+ Bevacizumab 455.53 0.0143
Recurrent Bevacizumab + OTX 008 81.68 0.0204
VEGF-A & Gal-1 Co-localization
No treatment 1134.24 0.0130
OTX008 81.68 0.0225
Bevacizumab 2340.56 0.0072
OTX 008+ Bevacizumab 62.83 0.0194
Recurrent Bevacizumab + OTX 008 3.47 0.0317
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Bevacizumab treated and OTX 008 treated. CD 133 and Survivin 
had the highest expression in untreated while both single 
treatments had less but near equal amounts. The combinational 
treatment had the lowest expression of CD 133, Survivin, Ki-67, 
and Hif-1 α. This expressional analysis indicates that a dual therapy 
is the best option to combat the angiogenesis and hypoxia 
characteristics of the tumor microenvironment. VEGF-A expression 
was the highest in untreated and Gal-1 but there was still 
expression in the other models. VEGF-A has expression in the 
other models indicating it is still in the environment. The pixel area 
of fluorescence intensity illustrates the same results depicted in the 
images.   
Chapter 6: Conclusion 
     The evidence collected points towards Gal-1 expression playing 
a role in promoting GB survival and growth. GB in the presence of 
standard treatment methods utilizes Gal-1 to maintain angiogenesis 
and hypoxia of the tumor microenvironment. Inhibition of Gal-1 
leads to a decrease in cell viability (MTT assay) and an increase in 
apoptotic activity (Caspase 3). Endothelial cell proliferation and 
increase in Gal-1 expression in response to GB cells being treated 
with Bevacizumab or OTX 008 indicates Gal-1 expression rescues 
endothelial cell proliferation and angiogenesis capacities. Gal-1 
keeps expression of Hif-1 complex active even in the presence of 
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VEGF inhibition by Bevacizumab. These results show strong direct 
correlations between Gal-1 hypoxia, angiogenesis, and inhibition of 
apoptotic activity. 
These results are promising showing that Gal-1 plays an important 
role in maintaining the GB microenvironment and allowing for GB 
progression. The next steps to follow these experiments will take a 
closer look at the role that complex N-glycans are playing in the 
tumor microenvironment. Is it purely Gal-1 expression that drives 
recovery of angiogenesis or is it dependent upon the glycome 
profile of the microenvironment? A knockout with a specific 
antibody to block complex n glycans would enable to see if its an 
internal activation of Gal-1 in some sort of positive feedback loop or 
N-glycans allowing Gal-1 to bind and keep VEGFR2 pathways 
open. Next I would create a humanized mouse model with CD 34+ 
stem cells to implant human GB tumor samples in the brain. The 
focus of this experiment is to conduct survival analysis and look at 
populations of macrophages, NK cells, T cells, and dendritic cells. 
A clear understanding of the immune effector cell phenotype with or 
without Gal-1 inhibition will illustrate Gal-1 role in the immune 
microenvironment. These experiments will further identify and 
single out mechanisms of Gal-1 vs mechanisms of glycans in the 
tumor microenvironment. VEGF-A still had expression across 
blockage from Bevacizumab so research to identify if it binds to 
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other receptors or still has influence in TME could help answer 
questions to why Bevacizumab is not effective in patients and 
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